A renewed, ethical defense of placebo-controlled trials of new treatments for major depression and anxiety disorders
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- Ketamine for treatment-resistant depression: recent developments and clinical applications
- Empirical evidence against placebo controls
- Stepped care for depression and anxiety in visually impaired older adults: multicentre randomised controlled trial
- Treatment of anxiety and depressive disorders in patients with cardiovascular disease
- Anxiety and depressive disorders are associated with delusional-like experiences: a replication study based on a National Survey of Mental Health and Wellbeing
- Migraine and its psychiatric comorbidities
- What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? A longitudinal cohort analysis
- Randomised placebo-controlled trials of surgery: ethical analysis and guidelines
- Medicalising unhappiness: new classification of depression risks more patients being put on drug treatment from which they will not benefit
- ω-3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review